Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment.
Ankylosing spondylitis
C-reactive protein
Cardiovascular risk
Machine learning
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
07
2020
accepted:
28
08
2020
pubmed:
18
9
2020
medline:
18
9
2020
entrez:
17
9
2020
Statut:
ppublish
Résumé
The performance of seven cardiovascular (CV) risk algorithms is evaluated in a multicentric cohort of ankylosing spondylitis (AS) patients. Performance and calibration of traditional CV predictors have been compared with the novel paradigm of machine learning (ML). A retrospective analysis of prospectively collected data from an AS cohort has been performed. The primary outcome was the first CV event. The discriminatory ability of the algorithms was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC), which is like the concordance-statistic (c-statistic). Three ML techniques were considered to calculate the CV risk: support vector machine (SVM), random forest (RF), and k-nearest neighbor (KNN). Of 133 AS patients enrolled, 18 had a CV event. c-statistic scores of 0.71, 0.61, 0.66, 0.68, 0.66, 0.72, and 0.67 were found, respectively, for SCORE, CUORE, FRS, QRISK2, QRISK3, RRS, and ASSIGN. AUC values for the ML algorithms were: 0.70 for SVM, 0.73 for RF, and 0.64 for KNN. Feature analysis showed that C-reactive protein (CRP) has the highest importance, while SBP and hypertension treatment have lower importance. All of the evaluated CV risk algorithms exhibit a poor discriminative ability, except for RRS and SCORE, which showed a fair performance. For the first time, we demonstrated that AS patients do not show the traditional ones used by CV scores and that the most important variable is CRP. The present study contributes to a deeper understanding of CV risk in AS, allowing the development of innovative CV risk patient-specific models.
Identifiants
pubmed: 32939675
doi: 10.1007/s40744-020-00233-4
pii: 10.1007/s40744-020-00233-4
pmc: PMC7695785
doi:
Types de publication
Journal Article
Langues
eng
Pagination
867-882Références
Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018;30:137–43.
doi: 10.1097/BOR.0000000000000475
England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036.
doi: 10.1136/bmj.k1036
Eder L, Harvey P. Cardiovascular morbidity in psoriatic arthritis: what is the effect of inflammation? J Rheumatol. 2017;44:1295–7.
doi: 10.3899/jrheum.170534
Navarini L, Margiotta DPE, Caso F, Currado D, Tasso M, Angeletti S, et al. Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: an Italian bicentric study. PLoS One. 2018;13:e0205506.
doi: 10.1371/journal.pone.0205506
Navarini L, Margiotta DPE, Costa L, Currado D, Tasso M, Angeletti S, et al. Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. Clin Rheumatol. 2019;38:971–6.
doi: 10.1007/s10067-019-04442-3
Arts EEA, Popa C, Den Broeder AA, Semb AG, Toms T, Kitas GD, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74:668–74.
doi: 10.1136/annrheumdis-2013-204024
Shen J, Shang Q, Tam LS. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Transl Res. 2016;167:138–51.
doi: 10.1016/j.trsl.2015.05.006
Castañeda S, Nurmohamed MT, González-Gay MA. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2016;30:851–69.
doi: 10.1016/j.berh.2016.10.006
Bai R, Zhang Y, Liu W, Ma C, Chen X, Yang J, et al. The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis. Angiology. 2019;70:492–500.
doi: 10.1177/0003319718814309
Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK. Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol. 2005;32:516–23.
pubmed: 15742446
Papagoras C, Voulgari P, Drosos A. Cardiovascular disease in the spondyloarthritides. Curr Vasc Pharmacol. 2020;18(5):473–87.
doi: 10.2174/1570161117666190426164306
Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2013;31:612–20.
pubmed: 23406817
Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med [Internet]. 1997;127:621.
doi: 10.7326/0003-4819-127-8_Part_1-199710150-00007
Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31.
doi: 10.1136/ard.2009.113696
Pletcher MJ, Moran AE. Cardiovascular risk assessment. Med Clin N Am. 2017;101:673–88.
doi: 10.1016/j.mcna.2017.03.002
Arts EEA, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, et al. Prediction of cardiovascular risk in rheumatoid arthritis: Performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016;75:674–80.
doi: 10.1136/annrheumdis-2014-206879
Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110:420–4.
doi: 10.1016/j.amjcard.2012.03.044
Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;76:17–28.
doi: 10.1136/annrheumdis-2016-209775
Johnson KW, Torres Soto J, Glicksberg BS, Shameer K, Miotto R, Ali M, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71:2668–79.
doi: 10.1016/j.jacc.2018.03.521
Narain R, Saxena S, Goyal AK. Cardiovascular risk prediction: a comparative study of framingham and quantum neural network based approach. Patient Prefer Adherence. 2016;10:1259–70.
doi: 10.2147/PPA.S108203
D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53.
doi: 10.1161/CIRCULATIONAHA.107.699579
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–82.
doi: 10.1136/bmj.39609.449676.25
Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.
doi: 10.1136/bmj.j2099
Doukaki S, Caputo V, Bongiorno MR. Psoriasis and cardiovascular risk: assessment by cuore project risk score in Italian patients. Dermatol Res Pract. 2013;2013:389031.
doi: 10.1155/2013/389031
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. J Am Med Assoc. 2007;297:611–9.
doi: 10.1001/jama.297.6.611
Woodward M, Brindle P, Tunsfall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172–6.
doi: 10.1136/hrt.2006.108167
Perk J, Backer G De, Gohlke H, Graham I, J ZR-EH, Undefined. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC committee for practice guidelines (CPG). European Guidelines on. 2012.
Batten A, Thorpe J, Piegari R, Rosland A-M. A resampling based grid search method to improve reliability and robustness of mixture-item response theory models of multimorbid high-risk patients. IEEE J Biomed Heal Inform [Internet] United States. 2019. https://doi.org/10.1109/JBHI.2019.2948734 .
doi: 10.1109/JBHI.2019.2948734
Chen DR, Kuo WJ, Chang RF, Moon WK, Lee CC. Use of the bootstrap technique with small training sets for computer-aided diagnosis in breast ultrasound. Ultrasound Med Biol. 2002;28:897–902.
doi: 10.1016/S0301-5629(02)00528-8
Didona D, Romano P. On bootstrapping machine learning performance predictors via analytical models. 2014. https://arxiv.org/abs/1410.5102 . Cited 9 Jan 2020.
Henderson AR. The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clin Chim Acta. 2005;359:1–26.
doi: 10.1016/j.cccn.2005.04.002
Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32:369–89.
doi: 10.1016/j.berh.2019.01.002
Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis—a retrospective cohort study using routine data. Semin Arthritis Rheum [Internet]. 2012;42:140–5.
doi: 10.1016/j.semarthrit.2012.02.008
Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017;76:364–70.
doi: 10.1136/annrheumdis-2016-209315
Bengtsson K, Forsblad-d’Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther [Internet]. 2017;19. https://pubmed.ncbi.nlm.nih.gov/28521824/ . Cited 24 Aug 2020.
Huang Y-P, Wang Y-H, Pan S-L. Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis—a population-based longitudinal follow-up study. PLoS One [Internet]. 2013;8:e64155. https://doi.org/10.1371/journal.pone.0064155 .
doi: 10.1371/journal.pone.0064155
Peters MJL, Visman I, Nielen MMJ, Van Dillen N, Verheij RA, Van Der Horst-Bruinsma IE, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis [Internet]. 2010;69:579–81.
doi: 10.1136/ard.2009.110593
Kim J, Kang U, Lee Y. Statistics and deep belief network-based cardiovascular risk prediction. Healthc Inform Res. 2017;23:169–75.
doi: 10.4258/hir.2017.23.3.169
Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein. Rheumatology. 2009;49:536–41.
doi: 10.1093/rheumatology/kep393